PhillipsK., TannockI.F.: Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.J Clin Oncol,16: 3179–3190, 1998.
2.
BokemeyerC., KuczykM.A., KohneH.: Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.Ann Hemat,72: 1–9, 1996.
3.
FossaS.D., KayeS.B., MeadG.M.: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.J Clin Oncol,16: 716–724, 1998.
4.
CrawfordJ., OzerH., StollerR.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.N Engl J Med,325: 164–170, 1991.
5.
OzerH., ArmitageJ.O., BennettC.L.: 2000 update recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol,18: 3558–3585, 2000.
6.
DaleD., CrawfordJ., LymanG.H.: Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review.Proc ASCO,20: 1638A, 2001.
7.
CosierL.E., DjulbegovicB., KudererN.M.: Colony-stimulating factor treatment of established febrile neutropenia reduces overall costs: result of an economic model based on a meta-analysis of randomized controlled trials.Proc ASCO,22: 2117A, 2003.
8.
ClarkO., DjulbegovicB., DaleD.C.: Treatment with colony-stimulating factors improves clinical outcomes in patients with established febrile neutropenia: a meta-analysis of the randomized clinical trials.Proc ASCO,22: 689A, 2003.
9.
LymanG.H., KuderererN., GreeneJ.: The economics of febrile neutropenia: implications for the use of colony-stimulating factors.Eur J Cancer,34: 1857–1864, 1998.
10.
GomezH., HidalgoH., CasanovaL.: Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.J Clin Oncol,16: 2065–2069, 1998.
11.
ZagonelV., BabareR., MerolaM.C.: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.Ann Oncol,5(suppl. 2): 127–132, 1994.
12.
BennettC.L., SmithT.J., WeeksJ.C.: Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey.J Clin Oncol,14: 2511–2520, 1996.
13.
BennettC.L., BishopM.R., TallmanM.S.: The association between physician reimbursement in the US and the use of hematopoietic colonystimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from 1997 American Society of Clinical Oncology survey.Ann Oncol,10: 1355–1359, 1999.
14.
SwansonG., BergstromK., StumpE.: Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system.J Clin Oncol,18: 1764–1770, 2000.
15.
SilberJ.H., FridmanM., ShpilskyA.: First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.J Clin Oncol,16: 2392–2400, 1998.
16.
RiveraE., Haim ErderM., FridmanM.: First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.Breast Cancer Res,5: 114–120, 2003.
17.
MooreT., ShiftanT.A., KnightC.A.: A prospective trial assessing a risk model for filgrastim use on chemotherapy (CT) dose intensity (DI) in the adjuvant treatment of stage I-III breast cancer patients (BCP).Proc ASCO,20: 1778A, 2001.
18.
ScottS.: Identification of cancer patients at high risk of febrile neutropenia.Am J Health-Syst Pharm,59(suppl. 4): S16–S19, 2002.
19.
IntragumtornchaiT., SutheesophonJ., SutcharitchanP.: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.Leuk Lymphoma,37: 351–360, 2000.
20.
MorrisonV.A., PicozziV., ScottS.: The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.Clin Lymphoma,2: 47–56, 2001.
21.
LymanG.H., MorrisonV.A., DaleD.C.: Risk of first febrile neutropenia (FN) among patients receiving CHOP chemotherapy.Proc ASCO,21: 1430A, 2002.
22.
Ray-CoquardI., BorgC., BachelotT.: Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy.Br J Cancer,88: 181–186, 2003.
23.
BlayJ.Y., ChauvinF., Le CesneA.: Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.J Clin Oncol,14: 636–643, 1996.
24.
OrsaghT., GallagherJ., FeldtS.: Duration of therapy of colony stimulating factors in oncology.Proc ASCO,21: 99A, 2002.
25.
LuxonB.A.: Clinical considerations in pegylated protein therapy.From research to practice,3: 3–9, 2001.
26.
HolmesF., JonesS.E., O'ShaughnessyJ.: Comparable efficacy and safety profiles of onceper-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.Ann Oncol,13: 906–909, 2002.
27.
HolmesF., O'ShaughnessyJ., VukeljaS.: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.J Clin Oncol,20: 730–731.
28.
JohnstonE., CrawfordJ., BlackwellS.: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.J Clin Oncol,18: 2522–2528, 2000.
29.
GreenM.D., KoelblH., BaselgaH.: Randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.Ann Oncol,14: 29–35, 2003.
30.
VoseJ.M., CrumpM., LazarusH.: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.J Clin Oncol,21: 514–519, 2003.
